|
Safety and efficacy of study drug versus placebo for negative symptoms of schizophrenia Clinical Trials Info presented on Clinical Trials Search is not intended to be a substitute for certified medical advice, visits or professional assistance using a real physician. We are not physicians. Always consult your dr. about Safety and efficacy of study drug versus placebo for negative symptoms of schizophrenia conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Safety and efficacy of study drug versus placebo for negative symptoms of schizophrenia Clinical research trials and Safety and efficacy of study drug versus placebo for negative symptoms of schizophrenia health trials happen in many of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new drugs. The function of the studies / projects is to resolve particular human medical questions. Clinical trials are a popular manner for mDs, government agencies, and private sector corporations to discover remedies for all varieties of circumstances, like Safety and efficacy of study drug versus placebo for negative symptoms of schizophrenia. Safety and efficacy of study drug versus placebo for negative symptoms of schizophrenia Clinical Trials and other clinical trials allow volunteers to obtain healthcare treatment options before they are available to the masses. Some times the participants undergo professional assistance for free of charge, and occasionally they are paid for their time. Sometimes there is a cost for a Safety and efficacy of study drug versus placebo for negative symptoms of schizophrenia clinical trial. Human subjects often get the best healthcare available for their Safety and efficacy of study drug versus placebo for negative symptoms of schizophrenia condition. Dangers are a reality, however, and may include additional or frequent mD visits, healthcare dangers (potentially life-jeopardising), and/or the treatment being ineffectual. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Safety and efficacy of study drug versus placebo for negative symptoms of schizophrenia  Safety and efficacy of study drug versus placebo for negative symptoms of schizophrenia
Safety and efficacy of study drug versus placebo for negative symptoms of schizophrenia
For Condition: Schizophrenia
Status: Completed
Sponsor(s): Johnson & Johnson Pharmaceutical Research and Development, L.L.C. ,
Synopsis: This study is to determine the efficacy (how well the drug works), safety, and side effects of the study medication compared to placebo in the treatment of the negative symptoms of schizophrenia in adults.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/60 Years
Genders: Both
Protocol Entry Criteria: Inclusion: - Adults aged 18-60 - Current diagnosis of schizophrenia - Significant negative symptoms with few positive symptoms (e.g. hallucinations, delusions) and no evidence of major depression. - Female subjects of childbearing potential must test negative for pregnancy at the time of enrollment. - Subjects must be able to provide consent - Must be healthy based on medical exam, laboratory tests and electrocardiogram Exclusion: - Female subjects who are either pregnant or nursing. - Acute or unstable medical conditions - Diseases of the central nervous system - Subjects who are judged clinically to be at serious risk for suicide or violence - Subjects with delusional disorder, psychotic disorder NOS, schizophreniform, schizoaffective disorder, bipolar disorder, attention deficit/hyperactivity disorder, major depressive disorder,alcohol or drug dependence
Total Enrollment: 180
Location and Contact Information:
Segal Institute for Clinical Research
Miami, Florida, 33161
United States
Birmingham Psychiatry Pharmaceutical Studies, Inc.
Birmingham, Alabama, 35209
United States
Clinical Innovations
Santa Ana, California, 92705
United States
Research Strategies
Torrance, California, 90503
United States
Global Research & Consulting
Olean, New York, 14760
United States
Behavioral Medical Research of Staten Island, P.C.
Staten Island, New York, 10305
United States
Quantum Laboratories
Pompano Beach, Florida, 33064
United States
Vanderbilt University Medical Center
Nashville, Tennessee, 37212
United States
Alexian Brothers Behavioral Health Hospital
Hoffman Estates, Illinois, 60194
United States
Synergy Clinical Research
Chula Vista, California, 91910
United States
IPR
Cerritos, California, 90703
United States
University Hills Clinical Research
Irving, Texas, 75062
United States
Neurobehavioral Research
Lawrence, New York, 11559
United States
Bayley Seton Campus-Psychiatric Research Division
Staten Island, New York, 10304
United States
University of Mississippi Medical Center-Dept. of Psychiatry
Jackson, Mississippi, 39216
United States
University of Colorado
Denver, Colorado, 80262
United States
Milwaukee VA Medical Center
Milwaukee, Wisconsin, 53295
United States
NorthCoast Clinical Trials
Beachwood, Ohio, 44122
United States
Sierra Vista Hospital
Sacramento, California, 95823
United States
Community Clinical Research
Austin, Texas, 78756
United States
Berma Research Group
Hialeah, Florida, 33016
United States
Psychiatric Institute of Washington
Washington D.C., District of Columbia, 20016
United States
CNS Research Institute
Clementon, New Jersey, 14760
United States
Research Strategies
Torrance, California, 90503
United States
Med Psych Specialists, LLC
Atlanta, Georgia, 30340
United States
Midwest Center for Neurobehavioral Medicine
Oakbrook Terrace, Illinois, 60181
United States
MedLabs Research of Houston
Houston, Texas, 77057
United States
Optimum Health Services
La Mesa, California, 91942
United States
IPS Research
Oklahoma City, Oklahoma, 73103
United States
Additional Information:
Study ID Numbers: R209130-SCH-202;
Study Start Date: May 2003
Record last reviewed: December 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00063297
Other Schizophrenia Studies:
1. A Study of Galantamine as an Adjunctive Treatment to Atypical Antipsychotics in Schizophrenia Patients with Cognitive Deficits
2. Medication Adherence in Older People with Psychosis
3. Safety and efficacy of an anti-psychotic in subjects with schizophrenia
4. Treating Thought Problems in Patients with Schizophrenia
5. Neuroimaging of Dopamine Metabolism in Normal and Psychiatric Patients
Related Studies:
Other Schizophrenia Clinical Trials
Other California Clinical Trials
Other Santa Ana Clinical Trials
Safety and efficacy of study drug versus placebo for negative symptoms of schizophrenia
|
|
|
|
|
|
|
|
